Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 145INDUSTRY 23NIH 22NETWORK 16UNKNOWN 4OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Triple Negative Breast Neoplasms 1Small Cell Lung Cancer Extensive Stage 1Pathologic Complete Response 1Oesophagogastric Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, B-Cell, Marginal Zone 1HR+/HER2- Breast Cancer 1Congenital Abnormalities 1Breast Neoplasms 1

Interventions

Tamoxifen 10Docetaxel 8Trastuzumab 7Paclitaxel 6Letrozole 6Gemcitabine 6Exercise 6Control Groups 6exemestane 5Indocyanine Green 5Cyclophosphamide 5Carboplatin 5Anastrozole 5pertuzumab 4dalpiciclib 4Vinorelbine 4Doxorubicin 4Capecitabine 4pyrotinib 3Surgical Procedures, Operative 3Standard of Care 3Radiotherapy 3Radiation 3Mammography 3Fulvestrant 3Cisplatin 3ferumoxides 2Zoledronic Acid 2Tablets 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Breast Neoplasms × Epirubicin × Clear all
NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡